CSCO 2017: Theliatinib Phase I Results

Novel EGFR TKI Theliatinib: An Open Label, Dose Escalation Phase I Clinical Trial

Lin Shen, Li Zhang, Hongyun Zhao, Wenfeng Fang, Jifang Gong

Venue: Chinese Society of Clinical Oncology Annual Meeting
Session: Esophageal Cancer
Presenter: Jifang Gong
Date: Thursday, September 28, 2017